New York Prostate Cancer Treatment Expert Dr. David Samadi Discusses Cancer Care Spending to Reach $158 Billion by 2020
New York Prostate Cancer Treatment Expert Dr. David Samadi Discusses Cancer Care Spending to Reach $158 Billion by 2020
NEW YORK, NY–(Marketwire – January 31, 2011) – According to a new study by the National Institutes of Health, cancer treatment spending is expected to reach $158 billion by 2020. This represents an increase of 27% over 2010 which had been projected to hit $127.6 billion, with costs linked to breast cancer ($16.5 billion), colorectal cancer ($14 billion), lymphoma ($12 billion), lung cancer ($12 …
Read more on Marketwire
Categories: Breast Cancer Treatment Tags: $158, 2020, Billion, cancer, Care, David, Discusses, Expert, prostate, Reach, Samadi, Spending, Treatment, York
Eli Lilly second-quarter global total revenue increases 9% to $5.749 billion
Eli Lilly second-quarter global total revenue increases 9% to $5.749 billion
Eli Lilly and Company today announced financial results for the second quarter of 2010.
Read more on News-Medical-Net
Categories: Breast Cancer Radiation Tags: $5.749, Billion, Global, Increases, Lilly, revenue, secondquarter, total
Celgene to Buy Abraxis Bioscience for $2.9 Billion
Celgene to Buy Abraxis Bioscience for $2.9 Billion
Celgene Corp., the maker of blood cancer drugs, agreed to buy Abraxis BioScience Inc. for $2.9 billion in cash and stock to acquire a solid-tumor medicine.
Read more on BusinessWeek
Categories: Breast Cancer Chemotherapy Tags: $2.9, Abraxis, Billion, Bioscience, Celgene
Celgene Acquires Abraxis for $2.9 Billion
Celgene Acquires Abraxis for $2.9 Billion
Celgene’s purchase expands the company into the solid tumor cancer drug market.
Read more on TheStreet.com
In 2018, Sanofi-Aventis’s BSI-201 Will Garner Sales of $1.7 Billion in the Triple Negative Breast Cancer Drug Market
In 2018, Sanofi-Aventis’s BSI-201 Will Garner Sales of $1.7 Billion in the Triple Negative Breast Cancer Drug Market
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, Sanofi-Aventis’s BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Read more on PR Newswire via Yahoo! Finance